In fact, a majority of patients with colorectal cancer (CRC), ranking as the most prevalent cancers worldwide, would present primary or acquired resistance during anti-PD-1 mAb treatment 3, which seriously hinders its clinical application. Here, PDCD1 is linked to cancer.